Clinical trial
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
NCT00243191 · Sarcoma Alliance for Research through Collaboration, Other · Completed
Key facts
| NCT number | NCT00243191 |
|---|---|
| Title | Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans |
| Official title | Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans |
| Lead sponsor | Sarcoma Alliance for Research through Collaboration, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dermatofibrosarcoma Protuberans |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 18 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Oct 21, 2005 |
| Last update posted | Mar 29, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: